RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead
Stem-cell research is on the cusp of a breakthrough that could come as soon as 2025, and two biotech companies with promising therapies stand to gain, according to a new report from Maxim Group on Thursday.
Stem-cell research is on the cusp of a breakthrough that could come as soon as 2025, and two biotech companies with promising therapies stand to gain, according to a new report from Maxim Group on Thursday.
